Mood disorder treatments are useful both during mood disorder acute phases and during maintenance. However there is a large variability in the inter-individual pharmacological response pattern. It is therefore useful to identify responders prior to treatment. Many biological and non biological factors have been invoked in explaining it, in particular heritable factors appear to be relevant. We investigated the possible association between DRD2, DRD3, DRD4, GABRA1, 5HT2a, 2c, 1a, and TPH genes with the prophylactic efficacy of lithium in mood disorders. 125 subjects (BP=100/MD=25) were followed prospectively for an average of 53 months of lithium treatment. 5-HTTLPR was investigated for the response to the antidepressant fluvoxamine in 154 subjects (BP=46/MD=108). TPH variants were marginally associated with lithium outcome (p=0.046), none of the other markers showed associations(1-4). Fluvoxamine response was associated with 5-HTTLPR (p=0.003)(5); this finding was independently replicated with paroxetine(6).
|Number of pages||1|
|Journal||American Journal of Medical Genetics - Neuropsychiatric Genetics|
|Publication status||Published - Aug 7 2000|
ASJC Scopus subject areas
- Neuropsychology and Physiological Psychology